Optimising High-Potency Manufacture

News
Article

Pharmaceutical Technology Europe

Pharmaceutical Technology EuropePharmaceutical Technology Europe-06-01-2011
Volume 23
Issue 6

Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.

High-containment manufacturing, whether for an active pharmaceutical ingredient or finished drug product, requires specialized approaches in facility design, equipment selection, and manufacturing processes to achieve the desired levels of containment and minimize operator exposure. As with pharmaceutical manufacturing overall, science- and risk-based approaches to reach those goals serve as a crucial framework for optimizing high-potency manufacturing as well for specific elements in the process.

This article was also published in our US sister publication Pharmaceutical Technology and can be read here.

Recent Videos
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Jens Schmidt, associate director MSAT at Lonza
Roger Viney, PhD, chief commercial officer for ICE Pharma
Behind the Headlines, episode 7
Related Content